Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.
about
Cabergoline for preventing ovarian hyperstimulation syndromeCan dopamine agonists reduce the incidence and severity of OHSS in IVF/ICSI treatment cycles? A systematic review and meta-analysisOutcomes of assisted reproduction treatment after dopamine agonist -cabergoline- for prevention of ovarian hyper stimulation syndromeKinase insert domain receptor/vascular endothelial growth factor receptor 2 (KDR) genetic variation is associated with ovarian hyperstimulation syndromeThe non-ergot derived dopamine agonist quinagolide in prevention of early ovarian hyperstimulation syndrome in IVF patients: a randomized, double-blind, placebo-controlled trial.Effect of bromocriptine on the severity of ovarian hyperstimulation syndrome and outcome in high responders undergoing assisted reproductionCetrotide administration in the early luteal phase in patients at high risk of ovarian hyperstimulation syndrome: A controlled clinical study.Treatment results of high dose cabergoline as an adjuvant therapy in six patients with established severe ovarian hyper stimulation syndrome.Pronuclear embryo cryopreservation experience: outcomes for reducing the risk of ovarian hyperstimulation syndrome and for fertility preservation in cancer patients.Comparison of cabergoline and intravenous albumin in the prevention of ovarian hyperstimulation syndrome: a randomized clinical trialCabergoline for preventing ovarian hyperstimulation syndrome in women at risk undergoing in vitro fertilization/intracytoplasmic sperm injection treatment cycles: A randomized controlled study.The effectiveness of cabergoline for the prevention of ovarian hyperstimulation syndrome.GnRH analogues in the prevention of ovarian hyperstimulation syndromeCombination of cabergoline and embryo cryopreservation after GnRH agonist triggering prevents OHSS in patients with extremely high estradiol levels--a retrospective studyA unique human chorionic gonadotropin antagonist suppresses ovarian hyperstimulation syndrome in rats.Vascular endothelial growth factor receptor 2 (VEGFR-2) functions to promote uterine decidual angiogenesis during early pregnancy in the mouse.VEGF antagonist for the prevention of ovarian hyperstimulation syndrome: Current status.Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndromePharmacotherapy of ovarian hyperstimulation syndrome.Cabergoline as treatment of ovarian hyperstimulation syndrome: a review.Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis.British Fertility Society Policy and Practice Committee: prevention of ovarian hyperstimulation syndrome.Signal mechanisms of vascular endothelial growth factor and interleukin-8 in ovarian hyperstimulation syndrome: dopamine targets their common pathways.The effect of cabergoline on folicular microenviroment profile in patients with high risk of OHSS.Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS.Cabergoline administration prevents development of moderate to severe ovarian hyperstimulation syndrome and it contributes to reduction in ovarian volume.Ultrasound and hematological changes during early luteal phase in women at high risk for developing ovarian hyperstimulation syndrome.Comparison of Cabergoline and Quinagolide in Prevention of Severe Ovarian Hyperstimulation Syndrome among Patients Undergoing Intracytoplasmic Sperm Injection.Severe ovarian hyperstimulation syndrome: Can we eliminate it through a multipronged approach?Preventing ovarian hyperstimulation syndrome: cabergoline versus coasting.Melatonin treatment protects against acute spinal cord injury-induced disruption of blood spinal cord barrier in mice.Ovarian Hyperstimulation Syndrome: A Narrative Review of Its Pathophysiology, Risk Factors, Prevention, Classification, and Management.
P2860
Q24234591-85673CF1-F427-4A62-ABC7-99560EFE098CQ28278251-C77A2312-8716-45FC-8DBE-14CCF5471F26Q28831447-3956C758-DD6E-468D-B42D-95E9F17259B7Q33624231-A6F2B210-29DB-4B05-A352-09F46DB85548Q33731989-E738C40B-BD37-468B-8F62-32893A95B0BAQ34268686-1F08959D-5E09-4E5D-8D04-91912B9E00D5Q34443933-D5E97ADD-2690-4B7B-A7CF-965365906CBBQ34589550-9B2CD7D3-639D-41D6-B11F-F406192DC517Q34861656-473678E8-20F5-45B8-9E41-2AC352682048Q35782765-1F9CD1DD-692F-4D68-BC55-CD3B1A088FD6Q36262733-A9F456DD-3C19-49FE-9D43-EA35247FA8B3Q36567091-1C8D8EB1-254A-4585-8C01-F606B35DA2C5Q36957480-C38CA5E3-B616-43EB-9510-0E6A584731B7Q36966423-87EDAC74-66DB-4248-81C4-59E811FB42C6Q37281160-1F1001A3-2323-4B90-9F7A-5FEC4C7110B6Q37281164-59147148-55E0-4223-987B-9C178E43FFDAQ37624402-CA6596BA-ABE5-4921-996B-798DC2E95ECAQ37658045-DC321BA3-FE18-41A7-9243-636278947535Q37790385-C9DCD3CA-1C3F-4B36-8C94-F3A7EA3D7260Q38056538-E582F90C-D78A-44A8-8BB6-DA3A6BBEDF44Q38139085-056960C1-A288-4129-9A02-F368122D24FBQ38266109-D6C16B9F-C4F7-4C6D-BF27-E8820C94F63DQ43222884-DA3FB38D-5458-433A-B2C6-5EB1C43B862CQ44458778-9AE0E2D1-126A-427D-B996-63519F9D42F3Q45301872-0E4519F0-E3FD-41A8-B95B-9FE3BC1A57A4Q47142303-1781D1B5-A0AD-42E7-82B3-A46AE0760B99Q47653390-0DD2A5EF-2A90-4C62-AFBC-3BDCF98554A8Q48503605-24B11367-C5B3-4AC4-8820-C0491A64EF5CQ49541658-BAB1BD9F-9C38-403B-A5F3-BAC7E0D97A36Q50991217-9E9CC8ED-C0E4-4ECD-A357-4A975B58C0ACQ52654285-3D124A3D-63EE-470E-814D-7277B0B33BFEQ55279761-C1836E29-C184-44C5-80C3-69801E8EDDD6
P2860
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh-hant
name
Implantation is apparently una ...... tion treatment: a pilot study.
@en
Implantation is apparently una ...... tion treatment: a pilot study.
@nl
type
label
Implantation is apparently una ...... tion treatment: a pilot study.
@en
Implantation is apparently una ...... tion treatment: a pilot study.
@nl
prefLabel
Implantation is apparently una ...... tion treatment: a pilot study.
@en
Implantation is apparently una ...... tion treatment: a pilot study.
@nl
P2093
P356
P1433
P1476
Implantation is apparently una ...... tion treatment: a pilot study.
@en
P2093
Claudio Alvarez
Gabriela García
Isabel Alonso-Muriel
José Bellver
Juana Crespo
P304
P356
10.1093/HUMREP/DEM315
P407
P577
2007-10-04T00:00:00Z